ARA-290 (Cibinetide) Side Effects: What the Trials Actually Measured
REVIEWED BY
Marcus Reinhardt — Chemical Researcher, Lead Analyst & Peptide Research Advisor
Marcus Reinhardt is a chemical researcher specializing in sustainable materials and advanced formulation science, with research experience in compound development and health optimization. He reviews all Peptide Insider educational content for scientific accuracy, strength of supporting evidence, and practical relevance. Editorial team.
Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn
Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy
Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07
ARA-290 side effects are, on paper, the cleanest in this batch — and that is exactly the problem. Four placebo-controlled human trials between 2012 and 2017, in sarcoidosis and diabetic neuropathy, report some version of “no safety concerns were raised” (PMID 23168581) or “no potential safety issues were identified” (PMID 25387363). None publishes an adverse-event rate, a placebo comparison for tolerability, or a single named side effect, and none dosed for longer than 28 days. This page gives you everything those abstracts say about safety, then what “nothing reported” does and doesn’t mean for a research vial.
Quick Answer: The Most Common ARA-290 Side Effects
Unreported. Across the 22-person 2012 pilot, the 2013 sarcoidosis trial, the 2015 type 2 diabetes trial, and the 64-person 2017 phase 2b — all dosed for 28 days or less — no abstract names a single adverse event or reports an adverse-event rate for any arm. The 2012 investigators wrote that “no safety concerns were raised by clinical or laboratory assessments” (PMID 23168581); the 2015 team, “no potential safety issues were identified” (PMID 25387363); the 2013 and 2017 abstracts don’t address safety at all (PMID 24136731, PMID 28475703). A 2014 review calls this an “excellent safety profile” (PMID 24555851) — over exposures that never exceeded 28 days. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.
The most complete “user experience” of ARA-290 that exists belongs to the people who took it under observation: 22 sarcoidosis patients in the 2012 pilot (12 on ARA 290, 10 on placebo), 64 in the 2017 phase 2b, and two further placebo-controlled trials — 2013 and 2015 — whose abstracts don’t state enrollment. The typical arc: 28 days of dosing, neuropathic symptoms improving, corneal nerve fibers increasing under confocal microscopy, and no adverse event the investigators considered worth an abstract sentence.
How tolerable did participants find it? No rate was published. What we can quote: “No safety concerns were raised by clinical or laboratory assessments” (2012) and “No potential safety issues were identified” (2015). In the 2012 pilot, pain and fatigue scores improved “significantly but equivalently in both patient groups” — placebo did as well as the drug on those measures.
What that experience came with: a confirmed diagnosis of sarcoidosis or type 2 diabetes, pharmaceutical-grade product from Araim Pharmaceuticals, blinded monitoring, and a 28-day ceiling on exposure — none of which ships with a research vial.
Compiled from the published trials (PMID 23168581, PMID 24136731, PMID 25387363, PMID 28475703) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Looking for Lab-Tested Peptides?
Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.
Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.
In This Guide
- What Is ARA-290 (Cibinetide)?
- How It Works — An EPO Fragment Built to Skip the Blood
- The Trial Numbers That Matter
- Adverse-Event Rates: What Four RCTs Did and Didn’t Report
- The Erythropoietin Question: The Side Effect It Was Built Not to Have
- Injection-Site Reactions
- Beyond Safety Sentences: The Systemic Effects the Trials Did Measure
- What Users Report: Self-Reported Effects From Reddit
- When Side Effects Happen — and When They Fade
- Long-Term Safety: What 28 Days Can and Can’t Tell You
- Who the Trials Enrolled — and Why It’s Nothing Like a Research Buyer
- Managing and Minimizing Side Effects: What the Trials Did
- Dose and Side Effects: Three Doses, No Safety Gradient Published
- ARA-290 Alone vs Stacked: What the Data Covers
- How ARA-290 Compares to Other Inflammation and Nerve Peptides
- Where the Trial Data Stops: The Research-Vial Reality
- Sourcing and Verification
- US Regulatory Status
- Frequently Asked Questions
- Glossary of Terms
What Is ARA-290 (Cibinetide)?
ARA-290 — cibinetide in the later clinical literature, ARA 290 in the early Mol Med papers — is a small peptide engineered from the structure of erythropoietin (EPO) to do half of EPO’s job. EPO protects tissue and stimulates red blood cell production; ARA-290 was designed to interact selectively with the “innate repair receptor” that mediates tissue protection, without stimulating erythropoiesis (PMID 25387363, PMID 24555851). Developed by Araim Pharmaceuticals, it was studied in small fiber neuropathy — loss of the thin nerve fibers carrying pain and temperature signals — in sarcoidosis and type 2 diabetes. On the research market it is sold as a nerve-repair and anti-inflammatory peptide, on the strength of trials that measured efficacy carefully and safety in a sentence.
How It Works — An EPO Fragment Built to Skip the Blood
The 2015 abstract states the rationale: erythropoietin “ameliorates experimental type 2 diabetes with neuropathy,” but “serious side effects limit its potential clinical use” (PMID 25387363). ARA-290 was engineered to be nonhematopoietic — a peptide “designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, antiinflammation and healing” (PMID 23168581). In humans it increased corneal small nerve fiber density (PMID 24136731) — a compound that regrows nerve fibers in 28 days is doing something substantial. The side-effect question is whether that has a cost, and the abstracts’ answer is that none was observed in the time they looked.
KEY TAKEAWAY
ARA-290’s entire side-effect thesis is subtractive: take EPO, remove the part that raises red cell mass, keep the part that protects tissue. The abstracts assert the design (“nonerythropoietic,” “does not stimulate erythropoiesis”) and report no safety concerns — but publish no hemoglobin or hematocrit values showing the subtraction worked. Design intent and demonstrated outcome are different things.
The Trial Numbers That Matter
The 2012 pilot: 22 sarcoidosis patients with symptoms of small fiber neuropathy and a spontaneous pain score of 5 or more on the Brief Pain Inventory, randomized to ARA 290 2 mg intravenously three times weekly (n = 12) or placebo (n = 10) for 4 weeks (PMID 23168581). The 2013 trial: blinded, placebo-controlled, 28 days of daily subcutaneous ARA 290 in sarcoidosis patients with documented small nerve fiber loss — the abstract states neither enrollment nor dose, and the paper carries a published erratum (PMID 24136731). The 2015 phase 2: type 2 diabetes with painful neuropathy, ARA 290 4 mg or placebo self-administered subcutaneously daily for 28 days, then a further month untreated for a 56-day observation window; enrollment not stated (PMID 25387363). The 2017 phase 2b: 64 subjects with sarcoid-associated small nerve fiber loss and neuropathic pain, randomized to cibinetide 1, 4, or 8 mg/day or placebo for 28 days (PMID 28475703). A 2014 review summarizes the two sarcoidosis phase II trials (PMID 24555851). Everything below draws on these five sources.
Adverse-Event Rates: What Four RCTs Did and Didn’t Report
Every safety statement in the four trial abstracts, in full. 2012: “No safety concerns were raised by clinical or laboratory assessments” and “ARA 290 appears to be safe in patients with sarcoidosis” (PMID 23168581). 2015: “No potential safety issues were identified” (PMID 25387363). 2013: nothing — the abstract reports symptoms, corneal nerve density, temperature sensitivity, and walk distance, and never mentions adverse events (PMID 24136731). 2017: nothing — nerve fiber area, GAP-43+ fibers, pain, walk distance, no adverse events mentioned (PMID 28475703). That is the whole ledger: no incidence for any event, no placebo comparison for tolerability, no severity grading, no discontinuation count, no laboratory value. Precisely: this is not evidence of harm, and not evidence of safety at the resolution a rate table gives. It is a small number of people, watched for 28 days, in whom investigators saw nothing they judged worth an abstract sentence.
PERSONAL OBSERVATION — PI EDITORIAL
Reading these four abstracts side by side, what struck us was the asymmetry of effort. The efficacy reporting is meticulous — confidence intervals on nerve fiber area to the square micron, correlations, a pain subgroup. The safety reporting is one sentence in two of them and zero in the other two. But in listings we’ve reviewed, “no side effects in clinical trials” is doing work that “no safety concerns were raised” cannot carry. Absence of a reported problem in 22 people over 4 weeks is a floor for the question, not a ceiling.
The Erythropoietin Question: The Side Effect It Was Built Not to Have
Every ARA-290 abstract makes the same claim: “a nonerythropoietic peptide engineered from erythropoietin” (PMID 25387363), “an erythropoietin derivative … that does not stimulate erythropoiesis” (PMID 24555851). That is the compound’s reason to exist: erythropoietin’s clinical use is limited by serious side effects, and a peptide that keeps the tissue-protective signaling while dropping the hematopoietic part would sidestep them. The key safety question: did hemoglobin, hematocrit, or red cell counts move in the people who took it? The abstracts don’t say. The 2012 trial’s “laboratory assessments” raising no concerns (PMID 23168581) is the closest any comes, and it is a summary, not a value. There is no signal in these sources; the point is that the marketing rests on a subtraction the abstracts assert rather than show. No blood-count data in these abstracts would let a buyer check whether a vial labeled ARA-290 behaves like the nonerythropoietic molecule or like a fragment of EPO. A COA confirms a sequence, not the biology.
Injection-Site Reactions
The abstracts report no injection-site reaction rates, or any injection-site finding at all. Route matters for context: the 2012 pilot gave ARA 290 intravenously, three times weekly (PMID 23168581); the 2013 trial moved to daily subcutaneous administration (PMID 24136731); the 2015 trial had diabetes patients self-administer 4 mg subcutaneously daily for 28 days (PMID 25387363). Daily subcutaneous injections for four weeks is the exposure a research buyer most resembles, and no subcutaneous abstract mentions the skin — consistent with unremarkable local tolerability, and with abstracts that didn’t itemize anything.
PRACTICAL NOTES — STANDARD SUBCUTANEOUS HANDLING
- The 2015 trial’s participants self-administered daily subcutaneous injections for 28 days — the closest published analogue to research-market handling
- Site rotation (abdomen, thigh, upper arm) is how trial protocols manage repeated daily injections
- Sterile technique — clean site, single-use needles — is non-negotiable in any protocol, trial or lab
- Our bacteriostatic water guide covers reconstitution handling in detail
Beyond Safety Sentences: The Systemic Effects the Trials Did Measure
For what ARA-290 does to a body beyond the nerve endpoints, the 2015 diabetes trial is the most informative — in a way “side effect” doesn’t quite capture. Subjects on ARA 290 “exhibited an improvement in hemoglobin A1c … and lipid profiles throughout the 56 d observation period” (PMID 25387363) — a shift in glycemic control and blood lipids that persisted a month after the last dose. In diabetic patients that is a benefit. In a person without diabetes, a compound that moves HbA1c and lipids is doing something systemic and unmeasured. The sarcoidosis trials recorded other systemic changes: cutaneous temperature sensitivity shifted and six-minute walk distance increased (PMID 24136731); in 2017, nerve fiber change correlated with walk distance (ρ = 0.645; P = 0.009) (PMID 28475703). In 2012, depressive symptoms (IDS) did not change (PMID 23168581). No abstract names a cardiovascular, hematologic, hepatic, or renal finding — in either direction.
What Users Report: Self-Reported Effects From Reddit
The four placebo-controlled trials above name no adverse event, but they ran 28 days or less in diagnosed patients; they cannot say what months of stacked research-vial use does. We searched Reddit on September 5, 2026, found 98 relevant posts from 2021 to 2026, and read the comment threads of eleven, across r/neuropathy, r/smallfiberneuropathy, r/BiohackingU, r/ResearchCompounds, r/Erythromelalgia and r/floxies. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified. Almost every poster has a disease that flares on its own; most inject other peptides too.
The most common negative report is pain or new tingling mid-course, which the community reads as nerves waking up. A poster with Sjogren’s-related neuropathy, titrating to 4 mg, developed painful pins and needles around both heels, stopped, and was mostly clear within two days; a pain doctor called it stimulation, not damage, and it returned on day nine of a second attempt (r/neuropathy, thread). A commenter who finished 28 days said fluctuating flares became sensitivity bad enough to seek help (thread). A small-fiber patient on about 3 mg a day posted a 21-day update mid-flare, with a numb hand and twitching, noting the same happened during a first two-week run before months nearly symptom-free (r/smallfiberneuropathy).
Feeling nothing is a real outcome. Two people ran it daily for eight weeks and sixty days with no change, one in a ten-year idiopathic neuropathy (r/neuropathy); another reported zero effect (thread); a commenter who finished a month at 2 to 4 mg a day said it did nothing (r/BiohackingU). The Sjogren’s poster whose thread title said the peptide had changed her life wrote six weeks later that three weeks at 4 mg gave no visible improvement; her day-eight breakthrough coincided with an electrical nerve stimulator she could not separate from it (thread).
When it works, people describe relief that fades when they stop, and cost decides how long they continue. The most-upvoted write-up followed the phase 2 protocol of 4 mg a day for 28 days: benefit arrived on day twelve and plateaued; the author reported no side effects and wondered whether it was healing or “an expensive pain relief protocol”; he was also on TRT and growth hormone (r/smallfiberneuropathy). A user with both small-fiber neuropathy and erythromelalgia said it helps the first for a few weeks before needing a washout and does nothing for the second (r/Erythromelalgia). A 16 mg kit at 2 mg every other day eased burning within a week but was, its author said, not a miracle (r/ResearchCompounds).
Almost nobody takes it alone, and the most alarming thread blames it least. A poster five weeks into retatrutide raised that dose and the same day added 4 mg of ARA-290 daily plus MOTS-c, then ran a fever and developed joint pain and skin that hurt like needles; stopping the additions left the poster still exhausted on retatrutide alone. Four commenters described their own sunburn-like skin sensitivity on retatrutide and pinned it there, two said fever pointed to a contaminated vial, and several said three new compounds at once made attribution impossible (r/BiohackingU). One commenter was starting it to treat retatrutide-induced allodynia (thread; see our retatrutide side-effects page). Elsewhere BPC-157 and TB-500 appear in at least six stacks.
The physical complaints are about the vial, not the molecule. One first injection was thick, cloudy and left a painful lump, which a reply blamed on unbuffered product gelling (thread); a user dissolving it in phosphate-buffered saline reported local injection reactions (thread); a 2021 thread includes repeated solubility troubleshooting (thread). Two effects stand alone: daily headaches from day three at 2 mg, which nobody echoed (thread), and morning dry mouth in a poster taking 20 mg every other day (thread). The erythromelalgia thread’s only user is the one above; the fluoroquinolone-injury thread drew no one who had taken it (r/Erythromelalgia, r/floxies).
HOW TO READ SELF-REPORTS
Trials and threads agree on one absence: nobody describes the red-cell, clotting or cardiovascular effects the molecule was built to avoid. Where they part is everything 28 days in diagnosed patients could not see: flares mid-course, months of cycling and stacks of other compounds, in people whose disease flares by itself. A handful report nothing; more report relief that ends with the injections; none of it yields a frequency or a cause.
When Side Effects Happen — and When They Fade
No ARA-290 abstract characterizes when adverse events occurred, because none reports any. The designs establish the observation window: 4 weeks of dosing in 2012 (PMID 23168581), 28 days in 2013 and 2017 (PMID 24136731, PMID 28475703), and 28 days of dosing followed by a month off-drug for a 56-day total in 2015 (PMID 25387363). That 2015 follow-up is the only published look at what happens after stopping, and it recorded persisting benefit on HbA1c and lipids rather than rebound. Any claim about ARA-290’s side effects beyond day 56 is a forecast.
Long-Term Safety: What 28 Days Can and Can’t Tell You
The longest dosing in any ARA-290 abstract is 28 days (PMID 24136731, PMID 25387363, PMID 28475703); the longest observation is 56 days (PMID 25387363). There is no open-label extension, no year-long study, no repeat-course data in these sources. Compare SS-31 (elamipretide), a batch sibling with a multi-year extension study — a different molecule for a different disease, so the comparison is about how much was measured, not about risk. For ARA-290, long-term human safety is uncharacterized in the published abstracts: not “good,” not “bad,” uncharacterized. Anyone describing ARA-290 over months of continuous use is describing something no trial did.
Who the Trials Enrolled — and Why It’s Nothing Like a Research Buyer
The 2012 pilot enrolled sarcoidosis patients with neuropathy and spontaneous pain of 5 or more on the Brief Pain Inventory (PMID 23168581). The 2013 trial enrolled sarcoidosis patients with documented small nerve fiber loss (PMID 24136731); the 2017 trial, 64 subjects with sarcoid-associated nerve fiber loss and neuropathic pain (PMID 28475703). The 2015 trial enrolled type 2 diabetics with painful neuropathy (PMID 25387363). Every safety sentence on this page was written about people with an immune-mediated or metabolic disease and confirmed nerve damage, under specialist care, for 28 days. The research buyer — typically without sarcoidosis or diabetes, hoping for nerve repair after an injury or an anti-inflammatory effect in a healthy body — appears in none of these abstracts, and no healthy-volunteer safety data exists in the sources we can cite. The evidence is real, and it is not about you.
Managing and Minimizing Side Effects: What the Trials Did
There was nothing to manage, according to the abstracts, so nothing was. No premedication, dose reduction, or titration schedule appears in any of the five sources. The structural choices are the only “management” on record: the 2012 pilot’s intravenous route gave way to subcutaneous self-administration by 2015 (PMID 23168581, PMID 25387363), and the 2017 trial tested three fixed doses rather than escalating (PMID 28475703). We report those as design decisions, not recommendations.
Dose and Side Effects: Three Doses, No Safety Gradient Published
The 2017 trial is the only multi-dose ARA-290 study: cibinetide 1, 4, or 8 mg/day against placebo for 28 days in 64 subjects (PMID 28475703). The efficacy result was not a staircase. Placebo-corrected change in corneal nerve fiber area was 109 μm² (95% CI -429 to 647) at 1 mg, 697 μm² (159 to 1236; P = 0.012) at 4 mg, and 431 μm² (-130 to 992) at 8 mg — the middle dose won, and the highest didn’t beat it. Pain improved significantly in all groups; among subjects with moderate-to-severe pain, the authors called the placebo-corrected decrease at 4 mg clinically meaningful, though it did not reach statistical significance (P = 0.157). The abstract gives no adverse-event count by dose, so the question a side-effects page most wants answered — did 8 mg cost anything 1 mg didn’t? — has no published answer. This is what the trials administered, cited; none of it is a protocol.
DID YOU KNOW
In the 2012 pilot, ARA 290 beat placebo on the neuropathy screening list — but on the Brief Pain Inventory and the Fatigue Assessment Scale, both groups improved “significantly but equivalently” (PMID 23168581). Ten people receiving placebo three times a week for 4 weeks got meaningfully less pain and fatigue. That is the placebo response in a monitored neuropathy trial — and the effect a research buyer with no control arm will attribute entirely to the vial.
ARA-290 Alone vs Stacked: What the Data Covers
Every safety statement on this page comes from ARA-290 alone against placebo; no combination trial appears in the abstracts. Research forums stack ARA-290 with the wound-and-tissue peptides — BPC-157, TB-500 — and none of those pairings has any human data, favorable or otherwise. The 28-day monotherapy record can’t be borrowed for a stack. All of these compounds are sold for non-human research use; their interactions have never been measured in a person.
How ARA-290 Compares to Other Inflammation and Nerve Peptides
No head-to-head trial exists, so this compares evidence, not rates, and the populations differ everywhere. In the anti-inflammatory and repair category, ARA-290 stands out for having placebo-controlled human RCTs at all — most compounds in our peptides for inflammation roundup and our KPV for inflammation guide have nothing comparable. What ARA-290 offers a side-effects reader: a stated pharmacological reason to expect a clean profile and structural evidence — corneal nerve fibers under a microscope — that it does something. What it lacks is a rate table. For pain contexts, our peptides for back pain and peptides for arthritis guides cover the usual comparators.
Where the Trial Data Stops: The Research-Vial Reality
Everything above describes ARA-290 supplied by Araim Pharmaceuticals and dosed in blinded trials. A lyophilized vial from a research storefront shares a sequence with that product and nothing else verifiable without testing. The gaps: identity and purity (a batch-matched COA is the only evidence the vial contains what the label says), concentration arithmetic (reconstitution with bacteriostatic water is on the buyer — our peptide calculator handles the math and deliberately nothing else), and no medical monitoring — “no safety concerns were raised by clinical or laboratory assessments” means clinicians ran labs and examined people; a research buyer has neither. Compounds in this channel are sold strictly for non-human research use.
Sourcing and Verification
ARA-290 has circulated on the research market for years on the strength of the Leiden trials — many listings, highly variable documentation. The checklist doesn’t change: a batch-matched COA naming the compound and quantity, independent third-party testing with a verifiable report number — our lab testing guide covers what to look for — and skepticism toward any listing calling it “proven safe” on the basis of 28-day trials that published no rates. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our Amino Club review shows what passing documentation looks like, our vendor directory lists who we’ve tested, and our guide library covers verification in depth. We don’t yet publish live ARA-290 prices.
US Regulatory Status
ARA-290 (cibinetide) is investigational: not FDA-approved for any indication as of this writing. The most recent placebo-controlled human result in our sources is the 2017 phase 2b (PMID 28475703). Practically: no prescription version exists to compare against, every vial in circulation is research-market material sold for non-human research use, and no regulator has evaluated any of those products for identity, purity, or safety. The FDA’s broader posture toward research peptides, covered in our report on the PCAC peptide vote, is the frame that applies to the vial.
PERSONAL OBSERVATION — PI EDITORIAL
In listings we’ve reviewed, ARA-290 is sold with more confidence than almost any compound in this batch, and the confidence comes from the absence of a reported problem. “No side effects in four human trials” reads like a strong claim until you notice that two of the four abstracts never mention safety and the other two summarize it in a sentence. Reading them next to elamipretide’s trials — which counted adverse events in both arms and published the split — the difference isn’t that one compound is safer. One was measured. Until an abstract puts a denominator under ARA-290’s safety, the COA is the only sentence on this page that applies to the vial.
Frequently Asked Questions
What are the most common ARA-290 side effects?
None are reported. Across four placebo-controlled trials in sarcoidosis and type 2 diabetes neuropathy, no abstract names an adverse event or gives a rate. The 2012 and 2015 abstracts say “no safety concerns were raised” and “no potential safety issues were identified”; the 2013 and 2017 abstracts don’t mention safety. No dosing exceeded 28 days.
Is ARA-290 the same as cibinetide?
Yes. ARA 290 is the development name used in the 2012–2015 Mol Med papers; cibinetide is the name used in the 2017 phase 2b. Both refer to the same nonerythropoietic peptide engineered from erythropoietin by Araim Pharmaceuticals.
Does ARA-290 raise red blood cell counts like EPO?
It was designed not to — every abstract describes it as nonerythropoietic or nonhematopoietic. However, none of the abstracts reports hemoglobin, hematocrit, or red cell values, so in these sources the claim is a design statement, not a published measurement.
Did ARA-290 work in its trials?
On the endpoints reported, yes. The 2012 pilot improved the small fiber neuropathy screening list versus placebo (Δ -11.5 ± 3.04 vs Δ -2.9 ± 3.34, p < 0.05). The 2017 phase 2b increased corneal nerve fiber area by a placebo-corrected 697 μm² at 4 mg (P = 0.012). The 2015 diabetes trial improved HbA1c, lipids, and PainDetect scores.
Is ARA-290 safe long-term?
Unknown. The longest dosing in any abstract is 28 days and the longest observation is 56 days. No extension study or long-term follow-up exists in the published sources, so long-term safety is uncharacterized — not established, not refuted.
Can you stack ARA-290 with BPC-157 or TB-500?
No human trial has tested ARA-290 in any combination. Every safety statement in the abstracts comes from ARA-290 alone against placebo over 28 days. Any stack’s profile is unmeasured, and there is very little monotherapy data to borrow from.
Glossary of Terms
- Innate repair receptor: the receptor ARA-290 was engineered to activate, mediating tissue protection and anti-inflammatory signaling without EPO’s blood-cell effects.
- Erythropoiesis: red blood cell production — the EPO action ARA-290 was designed to avoid; the abstracts assert this but report no blood counts.
- Small fiber neuropathy (SFN / SNFL): damage to the thin nerve fibers carrying pain and temperature signals; the condition studied in all four trials.
- Corneal nerve fiber density / area (CNFD / CNFA): confocal-microscopy measures of small nerve fibers in the cornea; the 2017 primary endpoint.
- GAP-43+ fibers: regenerating intraepidermal nerve fibers identified on skin biopsy; increased in the 4 mg group in 2017.
- Sarcoidosis: an immune-mediated inflammatory disease frequently complicated by small nerve fiber loss; three of the four trials enrolled these patients.
- Placebo-corrected change: active-arm change minus placebo-arm change — how the 2017 trial reported nerve fiber results.
References
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study — Mol Med, 2012 (PubMed)
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — Mol Med, 2013 (PubMed)
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Mol Med, 2015 (PubMed)
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Invest Ophthalmol Vis Sci, 2017 (PubMed)
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis — Expert Opin Investig Drugs, 2014 (PubMed)